The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 study of the oral vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor, rivoceranib, for recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC).
 
Hyunseok Kang
Honoraria - Axis Medical Education; Cancer Expert Now
Consulting or Advisory Role - Achilles Therapeutics; Bayer; Coherus Biosciences; Exelixis; GlaxoSmithKline; MitoImmune; PIN therapeutics; Prelude Therapeutics; Tempus
Research Funding - Ayala Pharmaceuticals (Inst); Elevar Therapeutics (Inst); Exelixis (Inst); Kura Oncology (Inst); Lilly (Inst); NeoImmuneTech (Inst); PDS Biotechnology (Inst); Prelude Therapeutics (Inst)
 
Myung-Ju Ahn
Honoraria - Amgen; AstraZeneca; Lilly; Merck Serono; MSD; TAKEDA; YUHAN
Consulting or Advisory Role - Alpha pharmaceutical; Amgen; AstraZeneca; Lilly; Merck Serono; MSD; Pfizer; TAKEDA; YUHAN
Research Funding - YUHAN
 
Jameel Muzaffar
No Relationships to Disclose
 
Bhumsuk Keam
Honoraria - AstraZeneca; Merck; MSD Oncology
Consulting or Advisory Role - ABL Bio; CBS Bioscience; Cellid; Handok; NeoImmuneTech; Trial Informatics
Research Funding - AstraZeneca; MSD Oncology; Ono Pharmaceutical
 
Daniel W. Bowles
Consulting or Advisory Role - Blueprint Medicines; Exelixis
 
Deborah J.L. Wong
Consulting or Advisory Role - Blueprint Medicines; Bristol-Myers Squibb; Genentech/Roche; Regeneron; Sanofi/Aventis
Research Funding - ARMO BioSciences (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); Elevar Therapeutics (Inst); Enzychem Lifesciences (Inst); FSTAR (Inst); Genentech/Roche (Inst); Kura Oncology (Inst); Lilly; Merck Serono (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Regeneron (Inst)
 
Alan Loh Ho
Consulting or Advisory Role - AffyImmune Therapeutics; AstraZeneca; Ayala Pharmaceuticals; Bristol-Myers Squibb; Cellestia Biotech; CureVac; CureVac; Eisai; Eisai; Exelixis; Genzyme; InxMed; Kura Oncology; McGivney Global Advisors; Merck; Novartis; Prelude Therapeutics; Regeneron; Rgenta; Sanofi; Sun Pharma; TRM Oncology
Speakers' Bureau - Medscape; Novartis; Omniprex America
Research Funding - Allos Therapeutics; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Ayala Pharmaceuticals; Ayala Pharmaceuticals; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Elevar Therapeutics; Genentech/Roche; Kolltan Pharmaceuticals; Kura Oncology; Lilly; Merck; Novartis; Novartis; Novartis; Novartis; Pfizer
Travel, Accommodations, Expenses - Ayala Pharmaceuticals; Ignyta; Janssen Oncology; Klus Pharma; Kura Oncology; Kura Oncology; Kura Oncology; Merck
 
Sung-Bae Kim
Stock and Other Ownership Interests - Neogene TC Corp, Genopeak; Neogene TC Corp, Genopeak
Honoraria - DAEHWA Pharmaceutical; ISU ABXIS
Consulting or Advisory Role - AstraZeneca; BeiGene; DAEHWA Pharmaceutical; Daiichi Sankyo/Astra Zeneca; ISU Abxis; Lilly (Inst)
Research Funding - Dongkook Pharma (Inst); Genzyme (Inst); Novartis (Inst)
 
Francis P. Worden
Honoraria - Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Merck Sharp & Dohme; Regeneron
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Loxo; Merck; Regeneron
Research Funding - Bristol-Myers Squibb (Inst); CUE Biopharma (Inst); Eisai (Inst); Lilly (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Bayer; Merck Sharp & Dohme
 
Tak Yun
No Relationships to Disclose
 
Suha Sari
Employment - Elevar Therapeutics
 
Maureen G Conlan
Employment - Elevar Therapeutics
 
Glenn J. Hanna
Honoraria - Bristol-Myers Squibb; Kura Oncology
Consulting or Advisory Role - Bicara Therapeutics; Boxer Capital; Bristol-Myers Squibb; Exicure; General Catalyst; Kura Oncology; Merck; Naveris; Prelude Therapeutics; Rain Therapeutics; Remix Therapeutics; Sanofi
Research Funding - Actuate Therapeutics (Inst); Bicara Therapeutics (Inst); Bristol-Myers Squibb (Inst); Conquer Cancer, the ASCO Foundation; Elevar Therapeutics (Inst); Exicure (Inst); Gateway for Cancer Research; Genzyme (Inst); GlaxoSmithKline (Inst); Kartos Therapeutics (Inst); Kite/Gilead (Inst); Kite/Gilead (Inst); NantKwest, (Inst); Regeneron (Inst); Secura Bio (Inst); V Foundation
Expert Testimony - Aaronson Rappaport Feinstein & Deutsch; Ahmuty, Demers, & McManus; Wilson Elser Moskowitz Edelman & Dicker, LLP